Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression

(2014) Noemi Reguart et al.   LUNG CANCER

EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition

(2013) T. Nakagawa et al.   CANCER RESEARCH

Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells

(2013) K. Shien et al.   CANCER RESEARCH

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

(2013) Tien Hoang et al.   INVESTIGATIONAL NEW DRUGS

Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?

(2013) Tony Mok et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

(2013) Marina Chiara Garassino et al.   LANCET ONCOLOGY

Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials

(2013) Yiliang Zhang et al.   OncoTargets and Therapy

Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non–Small-Cell Lung Cancer

(2012) Joel W. Neal et al.   JOURNAL OF CLINICAL ONCOLOGY

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

(2012) Ji-Youn Han et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

(2012) Samir E. Witta et al.   JOURNAL OF CLINICAL ONCOLOGY

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

(2012) King Pan Ng et al.   NATURE MEDICINE

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

(2011) Qing Zhou et al.   JOURNAL OF CLINICAL ONCOLOGY

Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors

(2010) Hui Song et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

(2009) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations

(2008) Kenji Sugio et al.   LUNG CANCER